Mohammad Azab - 19 Dec 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship: Director
Issuer ticker: XENE
Reported as of: 19 Dec 2023
Net transaction value: +$42,552
SEC form: 4
Accepted by SEC: 20 Dec 2023, 17:04:23 UTC
Prior SEC filing: 23 Jun 2023
Next SEC filing: 11 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Sherry Aulin, Attorney-in-fact

Key filing fact

Mohammad Azab filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 20 Dec 2023.

Key facts

This page summarizes Mohammad Azab's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Dec 2023, 17:04.

Change

Previous filing in this sequence was filed on 23 Jun 2023.
Current net transaction value: +$42,552.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XENE transaction

Common Shares

Options Exercise

Transaction value: $8,107
Shares: +823
Change %: +1.2%
Price: $9.85
Shares after: 70,728
Date: 19 Dec 2023
Ownership: Direct
Footnotes: F1, F2

XENE transaction

Common Shares

Options Exercise

Transaction value: $34,445
Shares: +3,497
Change %: +4.9%
Price: $9.85
Shares after: 74,225
Date: 19 Dec 2023
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -823
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Dec 2023
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 823
Exercise price: $9.85
Footnotes: F2

XENE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -3,497
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 19 Dec 2023
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 3,497
Exercise price: $9.85
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The common shares issued as a result of the exercise are subject to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023.

Footnote F2

The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.